{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:19:54Z","timestamp":1789395594774,"version":"build-2803163510"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":853,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Oxidized low-density lipoprotein (oxLDL) has been reported as an inhibitor of hepatitis C virus (HCV) cell entry, making it the only known component of human lipid metabolism with an antiviral effect on HCV. However, several questions remain open, including its effect on full-length cell-culture\u2013grown HCV (HCVcc) of different genotypes or on other steps of the viral replication cycle, its mechanism of action, and whether endogenous oxLDL shares the anti-HCV properties of<\/jats:bold>\n                                 <jats:bold>\n                                    in vitro\n                                 <\/jats:bold>\n                                 <jats:bold>\u2013generated oxLDL. We combined molecular virology tools with oxLDL serum measurements in different patient cohorts to address these questions. We found that oxLDL inhibits HCVcc at least as potently as HCV pseudoparticles. There was moderate variation between genotypes, with genotype 4 appearing the most oxLDL sensitive. Intracellular RNA replication and assembly and release of new particles were unaffected. HCV particles entering target cells lost oxLDL sensitivity with time kinetics parallel to anti-SR-BI (scavenger receptor class B type I), but significantly earlier than anti-CD81, suggesting that oxLDL acts by perturbing interaction between HCV and SR-BI. Finally, in chronically HCV-infected individuals, endogenous serum oxLDL levels did not correlate with viral load, but in HCV-negative sera, high endogenous oxLDL had a negative effect on HCV infectivity<\/jats:bold>\n                                 <jats:bold>\n                                    in vitro\n                                 <\/jats:bold>\n                                 <jats:bold>.<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion :<\/jats:title>\n            <jats:p>\n                                 <jats:bold>oxLDL is a potent pangenotype HCV entry inhibitor that maintains its activity in the context of human serum and targets an early step of HCV entry.<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.26190","type":"journal-article","created":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T20:34:18Z","timestamp":1354739658000},"page":"1716-1724","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Characterization of the inhibition of hepatitis C virus entry by In vitro \u2013generated and patient-derived oxidized low-density lipoprotein"],"prefix":"10.1097","volume":"57","author":[{"given":"Sandra","family":"Westhaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Bankwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Rohrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilka","family":"Wappler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Agn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Luchtefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Schieffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Sarrazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pietschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ciesek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"von Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20241201","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus.","volume":"17","author":"Lavanchy","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"R2-8-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2893.2011.01548.x","article-title":"Immunosuppression, liver injury and posttransplant HCV recurrence.","volume":"19","author":"Ciesek","year":"2012","journal-title":"J Viral Hepat"},{"key":"R3-8-20241201","doi-asserted-by":"crossref","first-page":"258","DOI":"10.4161\/rna.8.2.15011","article-title":"Hepatitis C virus and host cell lipids: an intimate connection.","volume":"8","author":"Alvisi","year":"2011","journal-title":"RNA Biol"},{"key":"R4-8-20241201","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.25501","article-title":"Role of lowdensity lipoprotein receptor in the hepatitis C virus life cycle.","volume":"55","author":"Albecka","year":"2012","journal-title":"HEPATOLOGY"},{"key":"R5-8-20241201","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/hep.21994","article-title":"Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81.","volume":"46","author":"Zeisel","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R7-8-20241201","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.282.5390.938","article-title":"Binding of hepatitis C virus to CD81.","volume":"282","author":"Pileri","year":"1998","journal-title":"Science"},{"key":"R8-8-20241201","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nature05654","article-title":"Claudin1 is a hepatitis C virus coreceptor required for a late step in entry.","volume":"446","author":"Evans","year":"2007","journal-title":"Nature"},{"key":"R9-8-20241201","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/nature07684","article-title":"Human occludin is a hepatitis C virus entry factor required for infection of mouse cells.","volume":"457","author":"Ploss","year":"2009","journal-title":"Nature"},{"key":"R10-8-20241201","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1210\/er.2001-0037","article-title":"The role of the highdensity lipoprotein receptor SRBI in the lipid metabolism of endocrine and other tissues.","volume":"24","author":"Rigotti","year":"2003","journal-title":"Endocr Rev"},{"key":"R11-8-20241201","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1126\/science.271.5248.518","article-title":"Identification of scavenger receptor SRBI as a high density lipoprotein receptor.","volume":"271","author":"Acton","year":"1996","journal-title":"Science"},{"key":"R12-8-20241201","doi-asserted-by":"crossref","first-page":"21003","DOI":"10.1016\/S0021-9258(17)31921-X","article-title":"Expression cloning of SRBI, a CD36related class B scavenger receptor.","volume":"269","author":"Acton","year":"1994","journal-title":"J Biol Chem"},{"key":"R13-8-20241201","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbalip.2009.11.005","article-title":"Scavenger receptor, Class B, Type I provides an alternative means for betaVLDL uptake independent of the LDL receptor in tissue culture.","volume":"1801","author":"Rohrl","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"R14-8-20241201","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1194\/jlr.M700355-JLR200","article-title":"Scavenger receptor BI facilitates the metabolism of VLDL lipoproteins in vivo.","volume":"49","author":"Van Eck","year":"2008","journal-title":"J Lipid Res"},{"key":"R15-8-20241201","doi-asserted-by":"crossref","first-page":"9120","DOI":"10.1074\/jbc.275.13.9120","article-title":"Dissociation of the high density lipoprotein and low density lipoprotein binding activities of murine scavenger receptor class B type I (mSRBI) using retrovirus librarybased activity dissection.","volume":"275","author":"Gu","year":"2000","journal-title":"J Biol Chem"},{"key":"R16-8-20241201","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1093\/emboj\/cdf529","article-title":"The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.","volume":"21","author":"Scarselli","year":"2002","journal-title":"EMBO J"},{"key":"R17-8-20241201","doi-asserted-by":"crossref","first-page":"8063","DOI":"10.1128\/JVI.00193-07","article-title":"Highavidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of highdensity lipoprotein.","volume":"81","author":"Catanese","year":"2007","journal-title":"J Virol"},{"key":"R18-8-20241201","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1128\/JVI.02356-06","article-title":"Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity.","volume":"81","author":"Grove","year":"2007","journal-title":"J Virol"},{"key":"R19-8-20241201","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2012.02.018","article-title":"Novel human SRBI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice.","volume":"57","author":"Lacek","year":"2012","journal-title":"J Hepatol"},{"key":"R20-8-20241201","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jhep.2010.06.024","article-title":"Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors.","volume":"54","author":"Syder","year":"2011","journal-title":"J Hepatol"},{"key":"R21-8-20241201","doi-asserted-by":"crossref","first-page":"31242","DOI":"10.1074\/jbc.M112.365924","article-title":"Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps.","volume":"287","author":"Dao Thi","year":"2012","journal-title":"J Biol Chem"},{"key":"R23-8-20241201","doi-asserted-by":"crossref","first-page":"18285","DOI":"10.1074\/jbc.M602706200","article-title":"High density lipoprotein inhibits hepatitis C virusneutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.","volume":"281","author":"Dreux","year":"2006","journal-title":"J Biol Chem"},{"key":"R24-8-20241201","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.21139","article-title":"Oxidized lowdensity lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells.","volume":"43","author":"von Hahn","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R25-8-20241201","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10557-011-6326-4","article-title":"Oxidized low density lipoproteinsdo we know enough about them?","volume":"25","author":"Jiang","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"R26-8-20241201","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/978-1-60327-029-8_24","article-title":"Oxidized lowdensity lipoprotein.","volume":"610","author":"Parthasarathy","year":"2010","journal-title":"Methods Mol Biol"},{"key":"R27-8-20241201","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1073\/pnas.76.1.333","article-title":"Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition.","volume":"76","author":"Goldstein","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R28-8-20241201","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI103182","article-title":"The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.","volume":"34","author":"Havel","year":"1955","journal-title":"J Clin Invest"},{"key":"R29-8-20241201","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/10715768909073429","article-title":"Continuous monitoring of in vitro oxidation of human low density lipoprotein.","volume":"6","author":"Esterbauer","year":"1989","journal-title":"Free Radic Res Commun"},{"key":"R30-8-20241201","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/hep.24610","article-title":"The green tea polyphenol, epigallocatechin3gallate, inhibits hepatitis C virus entry.","volume":"54","author":"Ciesek","year":"2011","journal-title":"HEPATOLOGY"},{"key":"R31-8-20241201","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1053\/j.gastro.2010.02.004","article-title":"Glucocorticosteroids increase cell entry by hepatitis C virus.","volume":"138","author":"Ciesek","year":"2010","journal-title":"Gastroenterology"},{"key":"R32-8-20241201","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.1128\/JVI.00212-11","article-title":"Impact of occludin intra and interspecies variation on its coreceptor function for authentic hepatitis C virus particles.","volume":"85","author":"Ciesek","year":"2011","journal-title":"J Virol"},{"key":"R33-8-20241201","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/hep.22673","article-title":"Development and characterization of hepatitis C virus genotype 17 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs.","volume":"49","author":"Gottwein","year":"2009","journal-title":"HEPATOLOGY"},{"key":"R34-8-20241201","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1128\/JVI.02199-08","article-title":"Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants.","volume":"84","author":"Catanese","year":"2010","journal-title":"J Virol"},{"key":"R35-8-20241201","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1128\/JVI.02200-09","article-title":"Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.","volume":"84","author":"Bankwitz","year":"2010","journal-title":"J Virol"},{"key":"R36-8-20241201","doi-asserted-by":"crossref","first-page":"12020","DOI":"10.1128\/JVI.01569-08","article-title":"Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.","volume":"82","author":"Grove","year":"2008","journal-title":"J Virol"},{"key":"R37-8-20241201","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1161\/01.ATV.16.8.1033","article-title":"Identification on human CD36 of a domain (155183) implicated in binding oxidized lowdensity lipoproteins (OxLDL).","volume":"16","author":"Puente Navazo","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R38-8-20241201","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/ars.2009.2733","article-title":"Oxidized LDL: diversity, patterns of recognition, and pathophysiology.","volume":"13","author":"Levitan","year":"2010","journal-title":"Antioxid Redox Signal"},{"key":"R39-8-20241201","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.clinre.2010.11.001","article-title":"Oxidized lowdensity lipoprotein is associated with viral load and disease activity in patients with chronic hepatitis C.","volume":"35","author":"Nakhjavani","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R40-8-20241201","first-page":"275","article-title":"Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assaysan evaluation with samples from the PIOstat study.","volume":"55","author":"Pfutzner","year":"2009","journal-title":"Clin Lab"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26190","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201305000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:46:47Z","timestamp":1733060807000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201305000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26190","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}